Tag: prostate cancer

1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer. 2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide. Evidence Rating Level: 1 (Excellent) Study Rundown: Enzalutamide is an approved therapy for...
1. Relugolix was shown to significantly decrease testosterone levels for a sustained period of time in male patients with advanced prostate cancer. 2. The risk of cardiovascular adverse events with relugolix therapy was found to be significantly lower than with leuprolide therapy. Evidence Rating Level: 1 (Excellent) Study Rundown: Long-acting injectable luteinizing...
1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer. 2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide. Evidence Rating Level: 1 (Excellent) Study Rundown: Enzalutamide is an approved...
1. In this prospective cohort, MRI-targeted biopsies alone, underestimated the histologic grade of prostate cancer tumors. 2. The combination of MRI targeted biopsy and systematic biopsy led to greater detection of all prostate cancers, and the upgrade of tumors to grade 3 or higher on histopathological analysis, upon radical prostatectomy,...
1. In men with prostate cancer, functional outcomes following moderately hypofractionated radiation therapy are clinically equivalent to those following conventionally fractionated radiation therapy. Evidence Rating Level: 2 (Good) External-beam radiation therapy (RT) is a primary radical treatment option for men with localized or locally advanced prostate cancer. The conventionally fractionated RT regimen...
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level:...
Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer, either alone or in combination with other treatment modalities. ADT, however, is not without long-term effects, with patients commonly experiencing sexual dysfunction, in addition to conferring an increased risk of cardiovascular events. ADT exposure may also increase...
There is a need for focal therapies for low to intermediate-risk prostate cancers, as whole-gland therapies have many complications without necessarily providing a survival benefit. Irreversible electroporation (IRE), a nonthermal ablative method based on forming nanoscale defects in cell membranes, has been proposed as a possible treatment. In this...
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study Oral live-attenuated polio vaccines (OPV) and injected inactivated polio vaccines IPV) have helped eradicate wild polioviruses. However, there is still a need to develop new vaccines...
1. This study evaluated the effects of post-diagnosis low-dose aspirin on prostate cancer-specific mortality and found no overall benefit. 2. The study did find a modest benefit in patients taking aspirin for at least 5 years after diagnosis. Evidence Rating Level: 2 (Good) Study Rundown: Several recent papers have suggested that regular,...